Related Experiment Video
Updated: Aug 7, 2026
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
Sublingual immunotherapy in the treatment of children
N Pham-Thi1, J de Blic, P Scheinmann
1Service de Pneumologie et Allergologie Pédiatriques, Hôpital Necker-Enfants Malades, Paris, France.
Insights
Sublingual immunotherapy (SLIT) can be effective for children with mild-to-moderate asthma and rhinitis, potentially preventing progression to asthma. Early initiation and long-term treatment are key for optimal outcomes.
Area of Science:
- Pediatric Allergy and Immunology
- Immunotherapy Research
Background:
- Asthma and rhinitis are common in children, often linked by the atopic march.
- Sublingual immunotherapy (SLIT) is a treatment option for allergic conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of SLIT in children with controlled intermittent mild-to-moderate asthma and rhinitis.
- To assess SLIT's impact on allergic progression and the development of new sensitizations.
Main Methods:
- Review of recent long-term clinical trials on SLIT in pediatric populations.
- Analysis of factors influencing SLIT compliance, including sociological, economic, and familial aspects.
Main Results:
- SLIT demonstrated efficacy in managing mild-to-moderate asthma and rhinitis in children.
- Evidence suggests SLIT interferes with the atopic march, preventing allergic progression from rhinitis to asthma.
- SLIT was associated with a blunted local immune response, indicating an immunomodulatory effect, and a reduced risk of new sensitizations without severe adverse effects.
Conclusions:
- SLIT is a viable treatment for select pediatric patients with allergic conditions.
- Early and prolonged SLIT initiation in childhood may enhance positive outcomes and prevent the progression of allergic diseases.
- Consideration of patient-specific factors is crucial for optimizing SLIT compliance and effectiveness.
Abstract:
Children with controlled intermittent mild-to-moderate asthma, controlled rhinitis and a single sensitivity may be appropriate candidates for sublingual immunotherapy (SLIT). Positive effects of SLIT may depend on initiation in early childhood and a long duration of treatment. To ensure optimum compliance, sociological, economic and familial factors should also be taken in to consideration when prescribing SLIT. Evidence from recent long-term trials indicates that SLIT interfered with the atopic march and the allergic progression from rhinitis to asthma without any severe adverse side effects. Local immune response has been seen to be blunted with SLIT, which suggests that treatment has an immunomodulatory effect. In addition, it may also decrease the risk of new sensitizations. Ongoing developments in SLIT, particularly advances in dosing and new indications, such as food allergies, will increase the use of this treatment modality in children.
